2101 completed, 468 terminated, 213 recruiting, 182 active not recruiting. 1058 Phase 2, 786 Phase 3, 627 Phase 1, 397 Phase 4, 47 Not applicable.
Follow Novartis Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation Abelacimab - Atrial Fibrillation (AF) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 2500 | 2027-12-30 | 2026-07-31 |
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria Coartem® Baby - Malaria | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 20 | 2027-06-18 | 2026-07-20 |
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients Radioiodine-refractory Differentiated Thyroid Cancer | Not yet recruiting | Novartis Pharmaceuticals | 200 | 2027-01-04 | 2026-10-15 | |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. Alpelisib, Fulvestrant, Trastuzumab - PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 51 | 2026-12-15 | 2026-09-18 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 186 | 2026-11-13 | 2026-10-20 | |
| A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia Spinal Muscular Atrophy | Not yet recruiting | Novartis Pharmaceuticals | 6 | 2026-11-01 | 2026-10-15 | |
| A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait Leukemia, Myeloid, Chronic-Phase | Not yet recruiting | Novartis Pharmaceuticals | 400 | 2026-10-30 | 2026-10-01 | |
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period Arumakimig, Placebo, Oral glucocorticoids - VEXAS Syndrome | Phase 2 | Recruiting | Novartis Pharmaceuticals | 120 | 2026-10-30 | 2026-10-13 |
| A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab Hidradenitis Suppurativa | Not yet recruiting | Novartis Pharmaceuticals | 34 | 2026-10-30 | 2026-09-21 | |
| A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy Plaque Psoriasis | Not yet recruiting | Novartis Pharmaceuticals | 3718 | 2026-10-30 | 2026-10-20 | |
| A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region Chronic Myeloid Leukemia | Not yet recruiting | Novartis Pharmaceuticals | 80 | 2026-10-29 | 2026-10-22 | |
| Design and Pilot Implementation of a Chatbot to Support Breast Cancer Screening Among Black Women Chatbot - Breast Cancer | Not applicable | Not yet recruiting | University of Washington | 873 | 2026-10-26 | 2026-10-05 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies NIO752, Placebo - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 48 | 2026-10-23 | 2026-10-09 |
| Pluvicto Real-world Investigation in Survival in Metastatic CRPC Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis | Not yet recruiting | Novartis Pharmaceuticals | 1085 | 2026-10-15 | 2026-07-22 | |
| A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS LOU064, Placebo - Hidradenitis Suppurativa | Phase 1 | Recruiting | Novartis Pharmaceuticals | 30 | 2026-10-15 | 2026-10-16 |
| A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates Hypertension | Recruiting | Novartis Pharmaceuticals | 500 | 2026-10-15 | 2026-10-21 | |
| A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis DDY391, Placebo - Moderate to Severe Psoriatic Arthritis | Phase 2 | Recruiting | Novartis Pharmaceuticals | 220 | 2026-10-14 | 2026-10-13 |
Showing 20 of 3189. Sign in to see all of them.
Breast Neoplasms (214) · Neoplasms (114) · Carcinoma, Non-Small-Cell Lung (109) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (92) · Pulmonary Disease, Chronic Obstructive (91) · Multiple Sclerosis (83) · Asthma (76) · Diabetes Mellitus, Type 2 (75) · Hypertension (73) · Prostatic Neoplasms (67) · Neoplasm Metastasis (62) · Recurrence (58) · Macular Degeneration (54) · Melanoma (52) · Heart Failure (51)
Everolimus (215) · secukinumab (151) · Imatinib Mesylate (87) · nilotinib (77) · Zoledronic Acid (76) · ribociclib (68) · sacubitril and valsartan sodium hydrate drug combination (65) · Letrozole (62) · canakinumab (62) · Panobinostat (60) · Ranibizumab (60) · Mycophenolic Acid (57) · Deferasirox (54) · Alpelisib (53) · Vildagliptin (52)
United States (1738) · Germany (1084) · Spain (786) · France (718) · Italy (714) · United Kingdom (641) · Canada (634) · Japan (477) · Belgium (476) · Australia (447) · Netherlands (438) · South Korea (404) · Poland (350) · Hungary (344) · Russia (344)
Annick Desjardins, MD, FRCPC (2) · Brandon Imber, MD (2)
PMID 35305260, PMID 38979716, PMID 42334791, PMID 31203228, PMID 33990512, PMID 36800111, PMID 37341961, PMID 41965705, PMID 17878242, PMID 18093207, PMID 21037195, PMID 34515338, PMID 34618347, PMID 36472162, PMID 26280447, PMID 27573260, PMID 27576559, PMID 33089502, PMID 33722947, PMID 34110605, PMID 34225229, PMID 34795065, PMID 37146227, PMID 37314061, PMID 38446397, PMID 20926833, PMID 23290985, PMID 23400739, PMID 23620574, PMID 26314396, PMID 27864013, PMID 30269054, PMID 31087226, PMID 31305131, PMID 32352653, PMID 33227175, PMID 33351179, PMID 33748660, PMID 33769862, PMID 34158598, PMID 34514815, PMID 34773130, PMID 34934034, PMID 35184572, PMID 35422096, PMID 37254256, PMID 37366061, PMID 37673211, PMID 38299639, PMID 38439079
2009 (84), 2023 (71), 2018 (54), 2016 (51), 2015 (49), 2008 (45), 2014 (43), 2017 (43), 2019 (40), 2025 (30), 2005 (16), 2004 (10), P30CA072720 (2), 1UF1AG046150-01 (1), P30CA015083 (1)